Hangzhou Tigermed Consulting : 2019 Sustainability Report

I

T

G

ME

R

E

D

01

TIGERMED

Sustainability Report

CONTENTS

LEADING CHANGE

While the world is facing unprecedented changes in decades, changing to respond to change and welcoming change over responding. Tigermed proactively adapts to changes in regulations, customer needs and social patterns, and keeps innovating its own mindsets, technologies and operational models to lead industry development.

Amidst complex changes, keeping a clear goal helps one stay on course. Tigermed stays true to the mission of "serving healthcare partners through innovation, advancing human health through excellence", and builds itself on the core values - honest & reliable, open & inclusive, collaborative & accountable, professional & innovative. Tigermed positions itself as a compliant business and works hand in hand with stakeholders towards sustainability.

CONTENTS

1. LEADER'S SPEECH

1. ABOUT TIGERMED

1. CORPORATE GOVERNANCE

16 FEATURE: COUNTERMARCHING, IN THE FIGHT AGAINST COVID-19

DRIVING INNOVATION
OF CLINICAL RESEARCH	20
POWERING GLOBAL MEDICAL INNOVATION	22
BECOMING A TRUSTED CLINICAL RESEARCH PARTNER	25
UPHOLDING QUALITY AS THE CORE OF THE BUSINESS
28
PROMOTING INDUSTRY
DEVELOPMENT	30
ACCELERATING THE DEVELOPMENT OF HEALTH INDUSTRY LOCALLY	32
SHARING IDEAS AND RESOURCES WITH INDUSTRY PEERS	34
BUILDING A STRONG TALENT POOL FOR HIGH-QUALITY INDUSTRY	36
DEVELOPMENT

GUIDING OUR PEOPLE IN THE
QUEST FOR SUCCESS	38
ENSURING EMPLOYEES' BASIC RIGHTS AND INTERESTS	40
ACTIVAING TALENT AND UNLEASHING POTENTIAL	42
FOSTERING AN ENGAGING TIGERMED CULTURE
44
CONTRIBUTING TO A
SHARED FUTURE	46
GREEN TIGERMED: STRENGTHENING	48
ENVIRONMENTAL MANAGEMENT
CARING TIGERMED: IMPROVING HEALTH	50
AWARENESS AT COMMUNITY LEVEL

1. KEY PERFORMANCE

1. OUTLOOK

56 HONG KONG STOCK EXCHANGE ESG (ENVIRONMENTAL, SOCIAL AND GOVERNANCE) REPORTING GUIDE INDEX

58 GRI (GLOBAL REPORTING INITIATIVE) INDEX

60 ABOUT THIS REPORT

02

01

TIGERMED

Sustainability Report

LEADER'S SPEECH

TO LEAD

TO INNOVATE

• We have deeply felt the profound changes of the era, thus upgrading ourselves proactively to adapt to changes in regulations, customer needs, and social and cultural patterns. We keep innovating our own mindsets, technologies, service and operational models to respond to changes in the pharmaceutical industry and the rapid growth of the Company. "

In the past 2019, Tigermed worked towards accelerating the launch of more innovative drugs for the benefit of patients. We yielded fruitful results and ushered in a number of important milestones.

During the year, the continued reform of China's drug and medical device reviewing and approval brought us new opportunities and challenges. We concentrated our efforts on innovative drugs and medical devices, and put more health products to the market to drive the development of innovative drugs in China. We were behind a number of innovative products, such as BeiGene's Zanubrutinib, the first FDA- approved anti-cancer drug developed in China, the first China- made biosimilar Rituximab Injection developed by Henlius, and the first China-made artificial heart "Yongrenxin". As of the first quarter of 2020, we had helped cumulatively 36 Chinese Class I innovative drugs go on the market, rendering patients more options.

In 2019, our projects passed numerous inspections with outstanding performance, and won wide recognition from customers. We took pride in the trophies and letters of thanks handed to us: Hua Medicine (Shanghai) granted us the Handin- Hand Progress Award; Hutchison MediPharma (Shanghai) bestowed Hangzhou Simo the Excellent Team Award; and 3DMed named Fantastic Bioimaging the Best Partner. We are chosen by more customers , and every year we remained

Dr. Ye Xiaoping

Co-founder and Chairman

100% of top ten customers. Such a success hinged upon the pragmatic cooperation of our clinical research team. Through industrial chain extension and regional service capacity building, we provided customers with all-round solutions, timely response and effective countermeasures to address their demands.

This year, we continued to expand our business landscape in the Asia Pacific Region, Europe and the United States, and further internationalized ourselves. We set up a joint venture with the Japanese company Accerise Inc. to provide international multi-center clinical trial services in Japan. Our first international multi-center clinical trial in Singapore enrolled the first subject. We acquired 100% stake in Tigermed-BDM Inc. in U.S. and integrated its data statistics and management resources into ours to adapt to global competition. By the end of the reporting period, we have set up 17 overseas operation sites across 12 countries and regions in the Asia-Pacific region, North America and Europe to fuel drug clinical trials by leveraging the wide-coverage service network. 2019 was a year of milestones. We released the first social responsibility report to demonstrate our responsibilities, commitments and practices. Our subsidiary, Frontage Holdings (1521 HK), launched a listing on the Hong Kong Stock Exchange to further globalize itself as a pharmaceutical CRO. Hangzhou Combak Hospital Co., Ltd. passed the GCP accreditation and obtained the Qualification Certificate of Drug Clinical Trial Institution. "Small Shield" APP developed by Hangzhou SlanHealth Co., Ltd., our investee, was successfully licensed as a medical device - an Auxiliary Management Software for Prevention Mother-to-Child Transmission of Viral Hepatitis B （VHB） by Zhejiang Medical Products Administration.

Product quality is the lifeline of Tigermed, and the foundation of all our accomplishments. Not long after our inception, we developed a quality management system in line with ICH-GCP Guideline to ensure project quality. We have fostered a quality culture to raise employees' quality awareness and gradually influence their work pattern and mindset. In the meantime, we incorporate the same quality standards into the supply chain to tighten quality management with suppliers. Our priority on quality wins us lasting trust from and cooperation with more customers.

Dedication of every employee has led to Tigermed's sustained and rapid growth. As talent is the most important asset of a CRO, we have developed management systems for talent selection, employment, training and retention, and customized management and training systems for professional and managerial personnel respectively. We are proud that our mid- level and above managers benefit a lot from internal training. Many employees have joined us right after graduation, grown

fast in work practice and are entrusted with key positions. Many senior managers are veteran employees who have worked with us for over ten years. We believe the development of the Company and the growth of employees go hand in hand.

We have witnessed the development of innovative drugs in China over the past 10 years. Drug innovation in China evolved from one man's fight to a battle of thousands of innovators, and in the meantime, the regulatory system keeps innovating in alignment with global practices. We have deeply felt the profound changes of the era, thus upgrading ourselves proactively to adapt to changes in regulations, customer needs, and social and cultural patterns. We keep innovating our own mindsets, technologies, service and operational models to respond to changes in the pharmaceutical industry and the rapid growth of the Company. Our robust growth is predicated on the commitment to corporate mission and values, and on compliance management, which underpin our ability to lead the change.

Looking forward to 2020, Tigermed will ride the trend of worldwide innovation and waves of continued reform in the Chinese pharmaceutical industry, and continue to fulfill its mission. We will adhere to the strategy of "Global Excellence, China Expertise", and align with high quality standards in the R&D of COVID-19 drugs. We will fuel the clinical development of more new drugs through efficient operation, and contribute to the health of humankind.

Ms. Cao Xiaochun

Co-founder and General Manager

02

03

TIGERMED

Sustainability Report

Solutions

ABOUT TIGERMED

Regulatory Affairs

Clinical Operations

Biometrics

Integrated Technology Services

ABOUT

TIGERMED

Hangzhou Tigermed Consulting Co., Ltd. is committed to supporting clients in their clinical development in the best possible way. As the leading clinical Contract Research Organization (CRO) in China, Tigermed is dedicated to provide services for new drug research and development and other supporting services to global and Chinese pharmaceutical and biotechnology companies. Since our inception in 2004, Tigermed has always embraced new technologies and partnerships to accelerate product development and generate the clinical evidence that our clients require to demonstrate real-world value.

The Company was listed on the Growth Enterprise Market (GEM) of the Shenzhen Stock Exchange (stock code: 300347. SZ) on August 17, 2012, and on the main board of the Hong Kong Stock Exchange on August 7, 2020 (stock code: 3347.HK).

Medical Devices / IVD

Post-Marketing / Real World

Evidence / Vaccine

Business Overview

Tigermed builds an integrated and all-round platform that covers the whole industrial chain of clinical research, and spans across the overall development cycle of new drugs and medical devices. In the pre-clinical stage, we offer bioanalysis, pharmaceutical research (including Chemistry, Manufacturing and Control), bio-equivalency (BE) trials, and PK/PD services. For Phase I to IV trials, our service covers project management and implementation, medical writing (such as clinical protocol and report), clinical monitoring, data management and statistical analysis, central imaging, pharmacovigilance, and site management organization (SMO). In addition, we provide regulatory submission & approval service, medical translation, Good Manufacturing Practice (GMP) qualification, training and auditing, and other integrated clinical services for medical devices from pre-clinical to post-launch stage.

04

05

TIGERMED

Sustainability Report

Mission

Serve healthcare

through innovation, Advance human health through excellence Vision

To be the recognized as the leading CRO

ABOUT TIGERMED

Honors

Tigermed

Values

& Reliable, Open & Inclusive, Collaborative & Accountable, Professional &

Brand slogan

Global Excellence, China Expertise

Trusted Clinical Research Organization partner

The 12th China Pharmaceutical Strategy Conference cosponsored by China National Pharmaceutical Industry Information Center and Taizhou Medical New & High-tech Industrial Development Zone's Management Committee

Innovative Chinese CRO of 2019

The 11th China Healthcare Summit of Entrepreneurs, Scientists, and Investors and Pharmaceutical Achievement Exhibition of the 70th Anniversary of the Founding of the P.R.C. held by China Pharmaceutical Enterprises Association and China Medicinal Biotech Association

"Top 10 Chinese Listed Pharmaceutical

Patient

Centric

By collaborating closely with regulatory agencies, medical research institutes, hospitals, and our global customers, we provide high-quality medical solutions for unmet patient needs.

Operational		Quality		Continuous
Excellence		Priority		innovation
We are committed to		We strictly abide by the		Looking forward
building a stable and		ethics and regulations		to the future, we
high-quality team		in clinical research		challenge ourselves
with a strong sense		and are committed		to explore innovative
of responsibility. We		to quality. To this		solutions internally and
provide professional		purpose, we provide		externally. Through
services and execute		standardized, efficient,		continuous optimization
efficiently through rapid		and proven clinical trial		and breakthroughs,
response and internal		services and we assure		we enable our clients
coordination.		product safety with a		to market their
		scientific, rigorous, and		products successfully

"2020 China Enterprise Credit Development Forum and the 11th Integrity Public Welfare Ceremony" held by China Enterprise Reform and Development Society Association and China Cooperative Trade Enterprises Association

2019 Top 500 Trustworthy Listed Companies in China

Companies in Investment Value of 2019";

and "Outstanding Enterprises of the

Pharmaceutical Industry in Celebration of

the 70th Anniversary of the Founding of the

P.R.C."

professional attitude.	worldwide and to
	ensure the sustainable
	development of our
	company.

1898

Number of total customers (by the end of the reporting

Hua Medicine (Shanghai) Ltd.		Hangzhou Municipal
	Bureau of Commerce
Hand-in-Hand Progress		Model Hangzhou
Award		Company in

Zhejiang Association for Corporate Social Responsibility

2019 Model Company in Corporate Social Responsibility

Headquartered in Hangzhou, Tigermed runs 123 service outlets in China's mainland, Hong Kong and Taiwan.To drive the internationalization of pharmaceutical R&D, the Company has also opened overseas subsidiaries and offices in 10 countries and regions, including Korea, Japan, Malaysia, the United States, Romania and Switzerland.

period)

130+

Service and Trade

in Zhejiang Province (for Practice Dimension)

SWITZERLAND		CANADA
ROMANIA	JAPAN	USA
INDIA	KOREA
MALAYSIA
SINGAPORE
	AUSTRALIA

Number of global branches and service outlets (as of Q1 2020)

36

Number of Class I Chinese innovative drugs successfully launched (as of Q1 2020)

According to the report of Frost & Sullivan,Tigermed has become the largest clinical CRO in China and among top ten in the world in terms of the operating revenue of 2019.

Hangzhou Simo

Hutchison MediPharma (Shanghai) Ltd.

Excellent Team Award

Beijing Cancer Hospital

2019 Beijing Cancer Hospital Best SMO Award for Clinical Trials

Fantastic Bioimaging

The District Economic Work Conference and Mobilization Meeting for Building the Strongest Digital Economy Zone held by Hangzhou High-Tech Zone (Binjiang)

Excellent Young Eagle Enterprise

3DMed

Best Partner Award

Frontage Laboratories

Life Science Leader magazine 2019 CRO Leadership Awards

06

07

Composition of the Fourth Board of Supervisors by Age:

TIGERMED

Sustainability Report

CORPORATE GOVERNANCE

CORPORATE

GOVERNANCE

Overview

In accordance with the law, we have established the general meeting of shareholders, the Board of Directors and the Board of Supervisors, launched a system of independent directors, and set up special committees under the Board. We have clearly defined the roles, powers, procedures and obligations of the general meeting, the Board of Directors, the Board of Supervisors and the management in decision-making, implementation and supervision. As a result, we have leveraged well according to the duties of authorities, decision-makers, business units, and supervisors, creating a governance mechanism of checks and balances. We act in strict accordance with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China and regulations, as well as the internal control system including the Articles of Association,

6

Number of general meetings of shareholders

15

Number of meetings of the Board of Directors

		We hold general meetings of shareholders as required, and facilitate shareholders'
		participation so that they can fully exercise their rights. Certain proceedings are
General Meetingof
followed for the deliberation of each proposal to ensure all shareholders are
Shareholders	treated equally. Shareholders' inquiries will be answered, and their suggestions and
opinions be listened to. The discourse right of small and medium shareholders will
		be ensured.
		We comprehensively consider age, education	Composition of the Fourth
		background, professional experience, skills,
		Board of Directors by Age:
Board of	and industry experience of directors to ensure
diversification of the Board. In April 2020, the	1	5
Directors	Company held a re-election for the fourth Board
		Membership which comprises three non-independent	Aged 40-49	Aged 50-59
		directors and three independent directors. Among
		them, 50% i.e.,three are female.

the Rules of Procedure of General Meeting, and the Procedural Rules of the Board of Directors to continuously improve the corporate governance system, and lay a solid foundation for regulated operations and sustainable development.

During the reporting period, as our international development strategy was further implemented, and the industrial chain continued to extend, we launched organizational reforms and built a "headquarters + business units" structure to empower the headquarters in creating value. We have established six business units and functional headquarters to better accommodate development needs.

8

Number of meetings of the Board of Supervisors

Board of

Supervisors

The Fourth Board of Supervisors comprises two shareholder supervisors and one employee supervisor, two of which are male and one is female. The shareholder and employee supervisors are respectively elected by the general meeting of shareholders and the Staff Representative Meeting. The term of office of supervisors is 3 years.

1	2
Aged 30-39	Aged 50-59

President Office of Administration

Finance Department

Audit Committee

Human Resources Department

Remuneration and

Evaluation Committee

Quality Assurance Department

Internal Audit

Department

Strategic Development

Data Resources and Compliance Department

Committee

Legal Affairs

Marketing and Business Development Department

Department

Nomination Committee

Executive Vice President

Policy and Regulatory Affairs Department

Board of

Directors

President / CEO

Government Affairs Department

Administration Department

Chief Operating Officer

Board Secretary

Procurement Department

Chief Financial Officer

Tigermed Investment

IT Department

Innovation Center

Preclinical and Generic Drug

Chief Science Officer

Business Department

Innovative Drugs Business Department

Medical Devices Business Department

Biometrics Business Department

SMO Business Department

New Industry Development Department

In accordance with the requirements of the relevant laws, regulations and the Management System for Investor Relations, the Company designated the secretary to the Board as the person-in-charge for the management of investor relations, who

Investor Relationshipis responsible for coordinating investor relations, receiving visiting Shareholders, answering enquires from investors and providing them with information already

Management disclosed by the Company. The Company responds to enquires from investors by means of phone calls, e-mails, interactive investor relations platform, investor relations section in the corporate website, investor reception day, etc, which enhances the exchange of information and promotes positive interactions with investors.

		The Company discloses its information in a true, accurate, complete and timely
		manner in strict compliance with the relevant laws and regulations and the
Information
Management System for Information Disclosure. During the reporting period, the
Disclosure	via the media outlets designated by the CSRC,namely The Securities Times and the
		Company issued a total of 4 periodic reports and 212 temporary announcements
		CNINFO website (www.cninfo.com.cn).

In 2019 2.78	269.9168
Dividend per 10 shares	Total cash dividend
(tax included) （RMB）	(including share repurchase in 2019) （million RMB）

08

09

TIGERMED

Sustainability Report

Raising Employees' Anti- corruption Awareness

Anti-corruption has been incorporated into our routine training. We cover all employees with anti-corruption training and assessment to raise their compliance awareness. During the reporting period, we provided special anti-corruption training to the management, including members of the Board, to enhance compliance awareness at the leadership level in clinical research and business operation.

Protecting the Rights and

Interests of Whistleblowers

Protection of privacy: The personal information and tips provided by the whistleblowers are kept strictly confidential. Other units, departments and individuals have no right to access the information unless authorized.

CORPORATE GOVERNANCE

Launching Internal Audits

We have established an internal supervision and management system composed of both business units and functional departments, such as risk supervision, compliance management, and audit departments. A multilevel supervision mechanism was also put in place to cover the headquarters, subsidiaries & branches and business units, to supervise and inspect the Company's financial status, operation & management, salary distribution, and the performance of directors and senior executives on either a regular or irregular basis. The audit department should inspect and evaluate the audit supervision of the headquarters and holding and joint-stock companies, and submit internal audit reports to the Board of Directors.

Strengthening Supply Chain

Compliance Management

We integrate compliance requirements for suppliers

Compliance Management

Tigermed's steady development cannot be separated from its culture of compliance, integrity and honesty. We strictly abide by national laws and regulations, international conventions and business ethics, and constantly improve the internal supervision mechanism and risk control system. We boost integrity management to adapt to increasingly stringent supervision and regulations, and live up to compliance requirements for internationalization.

100%

Coverage of staff anti-corruption training

In 2019

Guard against retaliation: We have set up a mechanism to guard against retaliation against informants. When the reports come from the inside, the Company will follow up to protect whistleblowers from workplace exclusion and retaliation. When the reports come from suppliers and partners, the Company will take measures to protect their rights and interests. Once it is confirmed that the informant has been retaliated, the Company will strictly deal with the personnel involved.

into our anti-bribery and anti-corruption policies. Cooperation is grounded on obser vance of the aforementioned requirements. Suppliers should sign a third-partyanti-bribery and anti-corruption statement in the bidding process, which specifies that suppliers shall not offer economic incentives in any form to Tigermed employees. With these measures, we swear to strengthen compliance management from the very start of the supply chain.

Anti-corruption

We conduct business with high ethical standards and strictly implement Policies of Anti-briberyand Anti-corruptionof Tigermed and Policies of Conflict of Interest. During the reporting period, we issued the Notice on Strengthening Compliance Management of Tigermed, and appointed compliance and data security officers to strengthen compliance management across the Company. As our presence in the global marketplace increases, we employ local legal consultants and develop standard operating procedures (SOP) to align operations to local policies and regulations. For example, we come up with Tigermed Physician Payments Sunshine Act referring to relevant regulations in the United States to meet compliance requirements.

According to the General Data Protection Regulation (GDPR) of the European Union, we have improved SOPs and management systems regarding legal affairs, IT and other departments involving personal information of project personnel. We invited European lawyers to carry out assessment and certification, and organized training sessions for all employees to enhance the awareness of personal information protection and compliance management.

		The column of "Compliance Concern" was opened up on the home page of our official website.
	Official website
	Informants shall fill in the form according to the guidance and may choose to report either
		anonymously or in real name.
		Tip-off hotline for noncompliant conducts: 400-687-272-02
	Hotline
		For anti-corruption and compliance: [e-mail];
	Email addresses
Clearing		For data security: [e-mail]
Reporting	The tips will go straight to our compliance officer / data protection officer, who will set up a
Channels	working group for investigation, and deal with the reported matters according to investigation
results. Since the establishment of the reporting channels, the Company has not received any
	reports on compliance violation.

10

11

TIGERMED

Sustainability Report

Risk management and control

We have built a corporate governance structure consisting of the general meeting of shareholders, the Board of Directors, the Board of Supervisors and the management, and a risk control framework of the internal audit department, audit committee and business QA with a clear division of duties, either of risk assessment or of risk management strategy. We have also set up risk assessment and control systems to standardize the management of business, finance, legal affairs, internal audit and information to improve security and guarantee sound and sustainable development.

IPR protection

We have put in place an intellectual property right management system. We manage intangible assets carefully, and strictly abide by provisions of our asset management system, scientific research management system, and personnel management system. And we actively reach out to the National Copyright Administration to apply for and renew software copyrights and utility

As of March 31, 2020

19

Number of registered patents

377

Number of software copyrights

CORPORATE GOVERNANCE

CSR Management

We work tirelessly to integrate social responsibility into corporate governance and operation, and push for sustainability management and practices. We also continuously deepen the harmonious relationship with stakeholders to safeguard health for mankind, fulfill social responsibility, and achieve sustainable development.

Leading organization and working mechanism

We have set up a well-coordinated organizational structure to promote sustainability management. As a decision-maker, the Board of Directors is charged with the top-level design of sustainable development affairs. The Social Responsibility Department, as a coordinator and supervisor, is responsible for promoting and monitoring implementation progress. The subordinate business units under the guidance of the headquarters perform CSR-related tasks as designated.

model patents.

Clinical trial ethics

We strictly follow the Declaration of Helsinki and include it in staff training in the hope of encouraging more employees to understand, support and participate in clinical research, and of accelerating the R&D of new drugs to contribute to public health.

100%

Coverage of ethics training for clinical trial practitioners

	Decision
	Board of Directors
	Maker
Coordinator	Social Responsibility
Department

Formulate sustainable development strategies and policies Supervise and review achievements in sustainable development

Implement resolutions of the Board of Directors on sustainable development

Communicate on and coordinate sustainable development issues

Prepare sustainability reports

				Manage ESG information on a daily basis
Executives	Subordinate Business
		Fulfill ESG management objectives
Units
				Provide timely feedback

Tigermed's Social Responsibility Management Mechanism

Goals and objectives

We continue to consolidate the foundation of social responsibility management. We focus on CSR management, responsible practices and sustainability branding to enhance the capacity for sustainable development and build competitiveness.

CSR management

Improve the sustainable development mechanism and put forth policies and systems to promote normalized CSR management

CSR practices

Fulfill social responsibility and summarize model cases in line with our sustainable development strategy and key sustainability concerns of the industry

Sustainability branding

Through releasing social responsibility reports (sustainability reports), we spread our sustainable development philosophy and gradually create a brand image as a sustainable enterprise.

12

13

TIGERMED

Sustainability Report

Sustainable relationship with stakeholders

We conscientiously identify and manage the impacts of our decisions and operations. We prioritize material topics closely related to our own development, and regard the government, shareholders, customers, employees, partners, environment, and community as important players propelling our continued development. We are committed to answering for each and every stakeholder.

CORPORATE GOVERNANCE

Material Topic Management

We refer to ISO 26000 Guidance on Social Responsibility, GRI Sustainability Reporting Standards issued by the Global Sustainability Standards Board, and Environmental, Social and Governance Reporting Guidelines of the Hong Kong Stock Exchange, to benchmark ourselves against outstanding practices in and outside China. Then, we proceed from the realities of the industry and our own conditions to identify material topics for us and our stakeholders.

To fully grasp the expectations and needs of stakeholders, we conducted research and survey (with 454 valid questionnaires collected), and analyzed material topics from two dimensions, namely "relevance to stakeholders" and "relevance to Tigermed's sustainable development" for accurate results.

We maintain active communication with all stakeholders. Through

Communication diversified mechanisms and channels, we listen to the voices and with Stakeholders concerns of all parties for mutual benefit and sustainable social

development.

Stakeholders

Government and regulators

Demands

Tax payment according to law

Compliance operation Fair operation

Communication channels

Inspection visits by leaders and competent departments Regular work summary and official document exchanges

Daily policy implementation

High
					Quality of products and services
				Protecting the rights and interests of subjects	Compliant operations
				Raising customers' satisfaction		Protecting the rights and interests of employees
Be		Information transparency	Tax payment according to law		Employee training and development
	Risk management	Employee welfare and care
toImportant			Work-life balance	Business		Occupational health and safety
	R&D ethics		performance
	Cultivating talentsFair operation
Responsible supply chain		R&D innovation
Raising environment protection awareness	Promoting industrial exchanges
stakeholders	Waste management		Resource conservation
	Environment management
		Industry-university-research integration
		Participating in industrial investment
		Coping with climate change
		Organizing public welfare activities
		Commitment to community health
low
	low	Be Important to Tigermed's sustainable development		High

Tigermed's Matrix of Material Topics

Shareholders and investors

Customers, including sponsors and hospitals

Partners

Employees

Communities and the general public

Creating jobs

Economic performance

Information transparency

Product and service quality

R&D ethics compliance

Reduce R&D costs

Improve R&D efficiency

Fair partnership

Responsible procurement

Protection of basic rights and interests

Personal growth and career development Work-life balance

Promoting community health

The general meeting of shareholders Information disclosure through regular reports and official website

Investors' hotline

Online platform irm.cninfo.com.cn of Shenzhen Stock Exchange

Customer visits

Daily communication by email and telephone

Customer satisfaction surve

Cooperation agreement

Industrial activities, such as exhibitions, and seminars

Internal emails

Internal publications

Channels of soliciting demands

Health knowledge seminars Public consultation and complaints

14

15

Sustainability Report	FEATURE: COUNTERMARCHING, IN THE FIGHT AGAINST COVID-19
TIGERMED

Rendering Immediate Support to Countermarchers on the Front Line

"I'm a mom.I'm racing for life."

--Li Mei, after learning that the potential drug was about to go through Phase III clinical trial, picked up the phone and

"This Spring Festival is meaningful.I'm heading out!"

--Guo Tingting, project manager, after hearing the news, immediately informed her family and rushed to the hospital for help.

FEATURE

Countermarching,

in the Fight Against

COVID-19

If one compares the fight against COVID-19 to a war without gunfire and smoke;

Then those people who risk their lives to grapple with the lethal virus are not born heroes sent from the heaven.

They are instead, ordinary people sacrificing their lives for the greater good.

Tigermed chose to countermarch in the looming shadow of the pandemic.

As the Spring Festival of the year of 2020 approached, COVID-19 spread rapidly from Wuhan to the whole China. The pharmaceutical industry was racing against the clock to find potential effective antiviral drugs and rush to put them in clinical trials.

Among them, one drug showed sound antiviral activity against SARS coronavirus and MERS coronavirus in early cell and animal experiments, and was regarded as a potential therapeutic drug in the early stage of the outbreak. It was of great significance to find out its clinical effect and to verify its efficacy and safety.

At this critical moment, employees of Tigermed were informed that the China-Japan Friendship Hospital had already kicked off the study in Jinyintan Hospital of Wuhan. They volunteered to step into the epicenter and threw themselves into the research. In addition to the clinical studies (for drugs, diagnostic reagents, and vaccines) at the onset of the pandemic, Tigermed donated money and supplies to the epicenter through specialized agencies. In the case of shortage of materials, the Company leveraged its own resources in the medical industry chain to purchase protective supplies for front-line medical personnel.

volunteered to help with the researcher just ten days after "Darling, wait for me back." giving birth to her child.

"Please, drive me there ASAP!"	--Cao Lianjun, project manager, left	"Count my dad in."
his months-old child and hurried off to
	the hospital to help researchers expedite	--Wan Yan, CRA based in Wuhan,
	trials.
--Gong Yunyan, CRA based in Beijing,	recommended her father as a
	volunteer to support transportation
asked her sister to drive her to commute		work during the Wuhan's lockdown.
between the hospital and printing stores.	"My baby will take pride in me."
With their efforts, our clinical trials got
approved.
	An Mingru, an expectant mother at 36
	weeks of pregnancy, still kept on working.

Issued by the Party Committee of Binjiang District of	Issued by Zhejiang Association for Corporate Social
Hangzhou City in recognition of the outstanding contribution	Responsibility in recognition of Tigermed's impressive sense of
of Tigermed during the fight against the pandemic.	social responsibility and patriotism reflected in the donations.
"Binjiang's Power in Anti-COVID-19 Fight"		2020 Outstanding Contribution Award of Zhejiang
Award	Enterprises in Anti-COVID-19 Fight

Letter of Thanks to the Family Members of Tigermed Staff

In the battle against COVID-19, we deeply appreciate the efforts of your families. It's an honor of Tigermed to have such a group of excellent employees. We believe they will be able to complete the task smoothly and look forward to their safe return.

Dr. Ye Xiaoping, Chairman of Tigermed

On January 25, 2020, Dr. Ye Xiaoping, Chairman of Tigermed, and Ms. Cao Xiaochun, General Manager of Tigermed, along with all Tigermed's medical staff, donated RMB 2.08 million to support the fight against COVID-19 in Wuhan.

Ms. Cao Xiaochun, General Manager of Tigermed

16

17

Sustainability Report	FEATURE: COUNTERMARCHING, IN THE FIGHT AGAINST COVID-19
TIGERMED

Delivering High-quality Service as Always

At 10:00 on January 23, 2020, Wuhan was locked down, and the fast-running city was put on hold.

However, our responsibility towards the sponsors and patients never ends.

After informed of the outbreak before the Spring Festival, Tigermed immediately established an emergency response team for epidemic prevention and control. We launched the business continuity plan (BCP), and made detailed arrangements for research projects with sponsors to minimize the impact of the pandemic.

After learning Wuhan's lockdown, our project team members in Wuhan took immediate actions. They entered the research center after obtaining permission to transfer project data urgently and keep the test drugs properly.

To minimize the impact of the pandemic on clinical trials and ensure the health and safety of subjects, CRAs and project managers, we introduced various solutions, such as online follow-up, online monitoring, and mailing samples and drugs,

The Wuhan team did a marvelous job for the recent projects. Hope they and their families are all fine.

• Tigermed delivered products on time despite the pandemic, and was highly praised by our American client.

Safeguarding Employees' Health Wholeheartedly

"Saving others is saving oneself."

Considering the pandemic and the unique nature of clinical trials, we pay high attention to the health and safety of employees.

We established the emergency response team, worked online, supported functional teams, provided one-on-one services, initiated employee assistance program (EAP), popularized protection knowledge, and sent our regards via the Labor Union…

Our care for employees permeate the slightest matters.

The pandemic tests the resilience of all enterprises. Despite the year- on-year decrease in business volume, we insist on no salary cuts and no layoffs to reassure our staff, and do our best to maintain social stability.

As of the date of this report, there was not a single case of infection or suspected infection in Tigermed.

Tigermed Timeline of Fight Against COVID-19

As a company specialized in medical and health services, we stay true to the mission of "serving healthcare partners through innovation, advancing human health through excellence". There are still cascades of difficulties in beating COVID-19. Therefore, we are pressing ahead with clinical trials of therapeutic drugs worldwide to secure the final victory of the battle, and contribute to public health.

to ensure uninterrupted clinical operations and medication supply to the subjects.

Issued a warning	Transferred clinical	In response to the government's appeal,
we extended the holiday, postponed work
company-wide to	materials and drugs	resumption and rolled out emergency response
stay vigilant about	during Wuhan's	plans for business operation. The functional
the epidemic.	lockdown.	departments introduced home office measures.
	January 20	January 23		February 2
	January 21		January 25	February 3
	Set up an emergency		Donated RMB 2.08	Tigermed staff arrived at Jinyintan
	response team headed	million to the Red	Hospital and officially joined the
	by the President.			Cross Society of China clinical trials.
				Zhejiang Branch.
Project members for COVID-19	Issued Tigermed's		Tigermed and
Requirements on COVID-19
potential drug clinical trial		Prevention and Control,		Hangzhou Simo were	Completed the
in Wuhan returned back to		specifying protection		among the first batch of
Hangzhou and Changsha and		measures after business		enterprises approved to	first subject
went on to a 14-day quarantine.	resumption.		resume work.	administration.
	March 28			February 12		February 10	February 6

April 15	March 20	February11	February 7
All project members	Successfully	Donated PPEs such as	Established Tigermed COVID-19
for COVID-19 potential	launched Tigermed	protective gowns, face	Prevention and Control Team
drug clinical trial in	Annual Conference	masks and gloves.	specifically for clinical trials project
Wuhan returned home.	online.		members in Wuhan.

18

19

TIGERMED

Sustainability Report

POWERING

GLOBAL MEDICAL

INNOVATION

BECOMING A

TRUSTED CLINICAL

RESEARCH PARTNER

UPHOLDING QUALITY

AS THE CORE OF THE

BUSINESS

DRIVING INNOVATION OF CLINICAL RESEARCH

Our Actions:

Provide clinical trial services and bring new and effective drugs to patients

Promote innovation and marketization of pharmaceutical products

Expand clinical research business in Asia Pacific, North America and Europe

Protect the basic rights and interests of subjects

Strengthen quality management and integrate quality control into the whole supply chain

Innovation is in the genes of Tigermed. The Company takes innovation as the key to harness changes in science and technology, in domestic and foreign pharmaceutical policies, and in customer demand. We embrace innovation in technology, management and service to speed up corporate development, facilitate global pharmaceutical R&D, and safeguard the health of mankind.

TIGERMED

Sustainability Report

DRIVING INNOVATION OF CLINICAL RESEARCH

POWERING GLOBAL

MEDICAL

INNOVATION

Under the policy guidance of the national pharmaceutical regulators, China's pharmaceutical industry has ushered in an era of boosting innovative drug R&D rather than confining itself to generic drug production. It is now more actively engaged in global pharmaceutical innovation. The development and application of innovative technologies such as big data and cloud computing also empower the digital transformation of the CRO industry.

As of Q1 2020

319

Number of clinical research projects of Class I Chinese innovative drugs Tigermed participated in

36

Number of Class I Chinese innovative drugs gained approval to market with the support of Tigermed

Facilitated the Marketing of the First Indigenous Anti-cancer Drug in the US

Case

Once, it was taken for granted that effective anti-cancer drugs are only developed by foreign companies. Only after years of marketing overseas can these drugs finally enter China, depriving many patients of the best timing for treatment. In November 2019, the U.S. Food and Drug Administration (FDA) approved Zanubrutinib, a novel anti-cancer drug independently developed by Chinese biomedical enterprise BeiGene. Zanubrutinib thus became the first China- developed anti-cancer drug approved by the FDA. Hangzhou Simo provided SMO services throughout the clinical research process, while Frontage Laboratories manufactured the experimental drug and conducted heart safety clinical studies for Phase I trial.

Powering Drug Innovation, Bringing Patients New Hope

Driving the "Go Global" of China's Innovative Drugs

China is now vigorously promoting the R&D of new drugs. It is committed to launching more innovative drugs to the market to endow patients with more options. Since its inception in 2004, Tigermed has developed a sound pharmaceutical R&D service system that provides integrated and comprehensive clinical trial solutions for innovative drug R&D.

In 2019

124

R&D investment （million RMB）

In 2019

116

Number of updated and

In the wave of the globalization of pharmaceutical R&D, China became a member of the International Conference on Harmonization (ICH) in 2017 and has aligned with global standards for more global cooperation. To accommodate the growing demands for overseas R&D projects, we actively plan our overseas business layout, and extend our businesses step by step to Asia Pacific, Europe and the United States to boost our international competitiveness and bring

Tigermed focuses on clinical trial operation services for

Tigermed provides other

improved SOPs for supporting global project cooperation

China's innovative drugs to the international arena.

innovative drugs, generic drugs and medical devices, as well as complementary services directly associated with clinical trial operations such as medical writing, translation and registration services and pharmacovigilance services.

Clinical trial	Clinical-related
services and
solutions	laboratory
	services

Services for Pharmaceutical Innovation

important services in the drug development process, including data management and statistical analysis, site management and patient recruitment, medical imaging as well as laboratory services.

4.43%

R&D investment to operating revenue

7

Among the 13 Class I drugs approved in China, 7 were developed with the assistance of

Participating in	Riding the trend of globalized pharmaceutical R&D, we actively carry out
international projects	multicenter trials worldwide.
Building
	strategic	We join hands with overseas pharmaceutical enterprises and laboratories
partnership	to promote innovation and research.

Contributed to the Approval of the First China-made Artificial Heart "Yongrenxin",	Case
creating a medical miracle to regain a new life by new heart

Patients with heart failure and in need of heart transplantation are often plagued by problems such as the lack of donors and the necessity of long-termanti-rejection and anti-infection treatments. The artificial heart has brought new hope for such patients. To break the monopoly of developed countries in the artificial heart technology and better address the needs of domestic patients, artificial heart "Yongrenxin" developed by Chongqing Yongrenxin Medical Devices was approved to be launched in the market in August 2019. Tigermed provided clinical research and technical services throughout the product's R&D. "Yongrenxin" fills the technical gap in the field of artificial heart in China. The innovative product will rekindle the hope of patients for life.

Tigermed or its subsidiaries.

Joining
	hands with	We communicate with overseas pharmaceutical organizations and learn
overseas organizations	from their best practices to narrow the gap.

The First Subject Successfully Enrolled in Singapore for International Multi-	Case
Center Trials

In July 2019, Jiangsu Alpha Biopharma Technology's study of the new generation of oral small- molecule reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) - AZD3759 successfully enrolled the first subject for a Phase II/III international multi-center trials and finished administration in Singapore. For Tigermed, this is the first international multicenter trial project and the first subject enrollment in Singapore, which sets a shining example for following research and development in Southeast Asian countries.

22

23

TIGERMED
Sustainability Report
Teddy Clinical Research Laboratory Established Strategic Partnership with MLM	Case
(European)

To better adapt to the trend of international multi-center clinical trial cooperation and meet
the needs of global customers, Teddy Laboratory has formally established strategic partnership
with MLM, a European based medical lab. Both sides will carry out extensive cooperation in
international multi-center trials and one-stop laboratory services.
Jiaxing Clinflash Officially Recognized as a Member of CDISC to Deliver High-	Case
Quality Service

As an active advocate of the globalization of clinical trials, Jiaxing Clinflash was recognized as a gold member of CDISC in May 2019. CDISC is a global open non-profit organization (NPO) of whole disciplines. It aims to integrate best practices in the industry and establish unified standards for clinical R&D, to support the electronic acquisition, exchange, submission, and archiving of clinical and preclinical data. Through CDISC's platform, Jiaxing Clinflash will continue to improve its system and service quality, meet CDISC standards, and enhance the efficiency and benefits of pharmaceutical enterprises.

Ushering in Organizational Reforms in the Digital Age

The digital reform in the medical industry has been unveiled and accelerated by COVID-19. We embrace the changes by integrating innovative technologies into our strategy and decision- making. We formulate prudent digital upgrade plans to keep up with the fast-pace industrial transformation, and shoulder due responsibility for customers and patients.

DRIVING INNOVATION OF CLINICAL RESEARCH

BECOMING A

TRUSTED CLINICAL

RESEARCH PARTNER

Tigermed's popularity among customers hinges on the hard-working and pragmatic clinical research team. We tirelessly extend the industrial chain and build regional service capacity to provide comprehensive and timely solutions, and strive to become a reliable clinical research partner for sponsors, clinical trial centers / researchers, and subjects.

Business data collection

Digital business scenarios

Digital culture

We appoint Chief Innovation Officer (CIO) for the first time. Through reasonable data use, we gradually build a digital management platform and an office collaboration platform to improve the transparency and efficiency of business operation, and lay a solid technical foundation for international collaboration.

We combine traditional business scenarios with digital technologies to facilitate the innovation, development and application of drugs.

We set up an innovation center to enhance the awareness of all staff at all levels, and tap into the potential of each employee for innovation.

The sense of mission is deeply embedded in the mind of Tigermed employees. We feel proud when the product we processed is marketed and benefiting patients. The recognition of customers is our perpetual source of motivation.

--Ms. Cao Xiaochun, General Manager of Tigermed

24

25

TIGERMED

Sustainability Report

Continuously Upgrading Service Capacity

To improve the efficiency of clinical trials, we build stronger professional service capacity to improve customer experience and protect the rights and interests of subjects. We strictly guarantee the security of clinical trials and research data to safeguard the privacy of all parties.

Improve the ability of
	Protect the rights and	Safeguard information
on-site service		interests of subjects		security

100%

Annual retention rate of top ten customers

DRIVING INNOVATION OF CLINICAL RESEARCH

We set up a clinical trial center management organization (Hangzhou Simo) to assist research institutions and researchers in clinical trial management. We have also developed standard operating procedures (SOP) for Hangzhou Simo to standardize management and improve the quality and progress of clinical trials. As of the first quarter of 2020, Hangzhou Simo had provided professional services in 956 sites across 106 cities.

We sign the Informed Consent Form with subjects beforehand to protect their right to be informed. And we provide sponsors and research institutions with patient health training and academic seminars to protect the safety, welfare and rights of subjects. By the first quarter of 2020, we had recruited over 7,100 subjects.

We formulate information security policies and specify the responsibilities and requirements of confidentiality, as well as the processing procedures and transfer requirements of personal data. We organize regular trainings for all employees to enhance their awareness of data and information security. During the reporting period, there was no major information leakage or data/agreement loss.

Voice from a CRC: Charging Forward with the Hope for Life

Case

In September 2019, Hutchison MediPharma (Shanghai) awarded top-performing suppliers for the first time, and Hangzhou Simo won Excellent Team Award.

Tigermed is home to teams of hardworking frontline staff in clinical trials, whose daily routine is
full of hustle and bustle. These people choose to march forward with the hope of marketing more
new drugs for public use.
"When will Patient 02 be here and has he made an	Patient A failed to store
appointment?" "The data for the interim analysis must be	urine samples from this
ready by next Wednesday.""The first PK blood sample of	morning as required;
subject 1001 was hemolyzed just now.Do we need to give	Patient B failed to
additional explanation?"		complete CT examination
	And he/she often	as scheduled; Patient
As a clinical research coordinator (CRC), he/	C refused to return for
must face such	safety follow-up.
she often says the following:	incidents:

As a CRC, one may thus feel	"I am a CRC, a bridge connecting doctors fighting for lives
discouraged, but always	and patients struggling to survive.To let patients access the
holds on to this belief:	latest treatment, Iwill not give up."

After years of arduous work, the new drugs are finally put on the market. Once again, in the battle between life and death, our clinical research team seizes the final victory.

Over the years, I have grown from a novice to a veteran with the memories of dozens of patients engraved on my mind. There were hard times when mounting difficulties blocked our way; and there were good times when the new drugs we worked on finally hit the market. Eventually, the good trumped the bad. Marketing a new drug, for doctors, subjects, and CRCs alike means hope for survival and for life.

--An anonymous CRC

According to the satisfaction survey results in 2019 (10 points in total)

9

Average score of PM satisfaction of sponsors / CRO

9.7

Average score of researchers' satisfaction of CRC

Establishing Complaint Handling Mechanism

As a service-oriented enterprise, customer satisfaction is our goal. We have built a comprehensive customer feedback mechanism which allows us to understand customer demand, timely solve problems, and improve customer satisfaction through visits, telephone calls, survey and other means of communication.

Receive complaint

Product Manager analyzes the complaint and forwards the message to relevant departments / Person in charge

Product Manager / Responsible departments / Person in charge handles the complaint (investigation, solutions, feedback, follow-up)

Post-solution survey

Customer Complaint Handling Mechanism

The Company keeps detailed records of customer complaints and divides them into four categories, namely major (key issues), moderate (serious issues), minor (general issues) and invalid complaints for efficient management. In 2019, we received 17 complaints from customers and handled all effectively.

26

27

TIGERMED

Sustainability Report

DRIVING INNOVATION OF CLINICAL RESEARCH

UPHOLDING QUALITY AS THE

CORE OF THE BUSINESS

Drug quality concerns life and death. Only by putting quality first can Tigermed gain a foothold in the market, win more trust and sustain long-term cooperation. We continue to optimize the quality management system, create a quality culture with full participation of staff, integrate quality control into the supply chain, and work with suppliers to ensure quality throughout the clinical research process.

Continuously Optimizing the Quality Management System

We build a quality control system composed of the Quality Management Committee, Quality Assurance Department and Internal Audit Department, and constantly upgrade the system by adopting the PDCA (Plan-Do-Check-Action) approach. In 2019, we integrated the SOPs of domestic and foreign subsidiaries to build a unified quality management system, and improved the current processes in line with the US and European regulations and the international strategy of Tigermed to better adapt to global development.

We formulated regulations and SOPs such as Measures of Handling Non-Compliance, and Corrective Action and Preventative Action to deal with major or serious quality incidents. Our Quality Assurance Department will investigate the incidents at once, implement handling measures, formulate corrective and preventive measures, and optimize the process according to the PDCA principle to control risks and prevent the recurrence of similar problems.

In 2019

13

Number of projects passing inspection by NMPA

15

Received 15 audits of both domestic and overseas customers with no major issues found, and the reception and follow-up work were highly recognized by our customers.

In 2019

4

Number of meetings on the quality management system

1

Number of annual meeting on quality management

In 2019

1604

Number of suppliers

1028

Domestic suppliers

576

Overseas suppliers

8

Number of supplier audits completed

Cultivating a Culture of Quality

High-quality clinical research results cannot be guaranteed without a powerful culture of quality. We focus on cultivating the quality awareness of employees during production and operation. Through orientation special training and regular trainings, we gradually change the way employees work and think, improve their awareness and make sure they understand and shoulder due responsibility.

Held the First Annual Quality Management Meeting to Improve Quality Awareness	Case
of the Leadership

In September 2019, Tigermed held the first annual quality management meeting in Shanghai. The meeting welcomed 72 senior managers, 66 of which were heads of departments of the headquarters and subsidiaries in China and 6 were from overseas institutions. The meeting, focusing on three themes: quality management, annual quality management activities and annual quality management audit reports, introduced the Company's annual quality management progress to the senior managers to consolidate the quality awareness of the management and clinical teams from top to bottom, and create a quality-oriented corporate culture.

Integrating Quality Control Into the Supply Chain

To control quality throughout the clinical research process, we incorporate supplier management into the SOPs, and formulate specific management procedures for suppliers engaged in clinical trials with key performance indicators. In this way, we aim to further integrate quality control into the supply chain, and work with suppliers to strengthen quality management.

supplier management	We have formulated the Supplier Management System to clarify the responsibilities and approval
economic, social and environmental risks threatening product quality and business ethics.
	Strict	authority of buying requisition, approval, purchase, acceptance, warehousing, payment, and
		inventory. We select suppliers based on principles like fairness and justice, full competition,
		integrity and self-discipline, and evaluate candidates from multiple dimensions to reduce
		We include supplier audit into the annual audit plan, and examine the quality performance of
	Supplier
	suppliers involved in clinical trials on a regular basis. We carry out on-the-spoton-cause audit of
	training to the establishment and improvement of the quality system through communication, to
audit	quality incidents, and understand the whole operation process from personnel qualification and
		help suppliers identify defects and enhance their quality management system.

28

29

TIGERMED

Sustainability Report

PROMOTING

INDUSTRY

DEVELOPMENT

Our Actions:

Fuel the development of regional healthcare industry

Establish platforms for industry exchange and cooperation

Cultivate talents for the industry Empower SMEs

As a leading clinical CRO in China, Tigermed leverages its experience, resources and expertise to build a sound and enabling healthcare ecosystem together with industry peers, contributing to health for all.

ACCELERATING THE

DEVELOPMENT OF HEALTH

INDUSTRY LOCALLY

SHARING IDEAS AND

RESOURCES WITH

INDUSTRY PEERS

BUILDING A STRONG TALENT POOL FOR HIGH-QUALITY INDUSTRY DEVELOPMENT

TIGERMED

Sustainability Report

ACCELERATING THE

DEVELOPMENT OF HEALTH

INDUSTRY LOCALLY

Rising health awareness has led to increasing public demands for high-quality healthcare. Tigermed seizes the opportunity to assist in the reform of local healthcare industry and capitalizes on the clinical research expertise and best practices it has built up over the years to expedite drug innovation and R&D, and benefit more patients.

	PROMOTING INDUSTRY DEVELOPMENT
Assisted in Developing National Biomedical Industry Base in Pingshan District,	Case
Shenzhen

The biomedical industry is developing rapidly in the Guangdong-HongKong-Macau Greater Bay Area, one of the most open and economically vigorous regions in China. Tigermed and Shenzhen Pingshan District People's Government have entered into cooperation to build an integrated service platform for clinical research. Building on Tigermed's expertise in the clinical research of drugs and medical devices as well as the solid foundation for developing the biomedical industry in Pingshan District, we make full use of local preferential policies and favorable business environment to empower more biomedical innovation companies in the area, and to make it a highland for biomedical innovation.

Tigermed has signed a framework agreement with Shenzhen Pingshan District People's Government to build an integrated service platform for clinical research.

Contributed to the Biomedical Industry in Wuxi

Case

Biomedicine is one of the strategic emerging industries of Wuxi City. Tigermed is the first partner of AstraZeneca in founding Wuxi International Life-Science Innovation Campus (iCampus). We hope to share best practices and achievements in international business with innovative pharmaceutical companies, help Chinese companies go international, and introduce foreign innovative drugs and medical devices into China. We are committed to building a patient- centered and innovation-enabling ecosystem across the entire industry chain.

Dr. Ye Xiaoping (right front), Chairman of Tigermed, attended the iCampus Signing Ceremony.

32

33

TIGERMED

Sustainability Report

SHARING IDEAS AND

RESOURCES WITH

INDUSTRY PEERS

Based on professional service capacity in new drug clinical research and rich global resources for collaboration, Tigermed strives to build a high-level exchange and cooperation platform for industry partners at home and abroad. Through sharing best practices and opinions, players in the industry could grasp new frontiers of the industry, come up with new ideas, and thereby generate continuous industry breakthroughs.

Sharing Experience

Early-stage clinical R&D is key to the development of innovative drugs. Tigermed held the Seminar on Early-Stage Clinical R&D of Innovative Drugs to create opportunities for industry peers to share experience and insights in this regard.

Tigermed organized the First Anhui Institutional Development Conference to strengthen ties between CROs and SMOs, and improve the efficiency and quality of clinical trials.

Tigermed, together with three subsidiaries: Talent MedConsulting, Frontage Laboratories, and Jiaxing Clinflash, participated in the Third New Drug Clinical Development Summit and shared requirements for new drug application and measures for clinical research risk control.

Tigermed and Korea National Enterprise for Clinical Trials (KoNECT) signed an MOU to promote exchanges, cooperation and experience sharing between CROs in the two countries.

Experience sharing for

GCP improvement

Tapping the enormous potential

of innovative biologic drugs

Tigermed shared ways to cut R&D expenditure and shorten the R&D cycle of biosimilars at the 2019 Biopharma Developer Innovation Conference & 1st Turning Point Annual Meeting, to expedite the "go global" of Chinese new drugs.

Tigermed exchanges with industry peers

Tigermed actively participated in major international conferences, such as the DIA 2019 Global Annual Meeting, the Biotechnology Innovation Organization (BIO) International Convention, BIO- Europe, Europe's largest biotechnology partnering conference, and the 38th Annual J.P. Morgan Healthcare Conference, where the Company shared the latest progress and achievements of China's clinical research with international counterparts and built a two-way bridge for high- quality medical products at home and abroad.

PROMOTING INDUSTRY DEVELOPMENT

At the 2019 China Clinical Trial Organizations . Innovation . Practice Summit Forum, Mr. Wu Qiang, Vice President of Tigermed Project Management Department, introduced the development situation of Chinese clinical trial organizations, and shared insights about opportunities and challenges brought by the new clinical trial policy. He also shared the experience of cooperating with clinical trial organizations.

Offering Advice and Suggestions for Industry Development

Tigermed participated in the seminar of ICH E8 (R1) Guideline on General Considerations for Clinical Trials organized by the National Medical Products Administration, and offered key takeaways from frontline practices to help push the Guideline to enter the third phase. In addition, Tigermed was invited to share its experience as a private enterprise in a meeting soliciting opinions for the Regulations on the Promotion of Private Enterprises in Zhejiang Province.

Ms. Chang Jianqing, Vice President of Tigermed Policy and Regulations, was invited to the DIA China Drug Discovery Innovation Conference, where she introduced key points relevant to clinical research in the Drug Administration Law of the People's Republic of China.

34

35

TIGERMED

Sustainability Report

PROMOTING INDUSTRY DEVELOPMENT

Our actions

Value contribution

BUILDING A STRONG TALENT POOL FOR HIGH-QUALITY INDUSTRY DEVELOPMENT

					Tigermed jointly established the Beijing
					Clinical Research Ability Training Center
		Giving			with Beijing Ditan Hospital, Capital Medical
				University.
				Tigermed co-opens courses on Clinical
		lectures			Trial Management with Zhejiang
				Pharmaceutical College and Hangzhou
				Tigermed built a China-South Korea
					Medical College.
					clinical research exchange and cooperation
					platform and sent lecturers abroad to give
					courses to international industry peers.
Forms of cooperation				20 universities and colleges including
					Tigermed offers internships for more than
		Internships
				Zhejiang Pharmaceutical College,
				Pharmaceutical University, and Guangxi
					Shenyang Pharmaceutical University,
					Nanjing Medical University, Beijing
					University of Chinese Medicine, Zhejiang
					Chinese Medical University, China
					Medical University.
		Scholarships			Tigermed set up the "Tigermed
					Scholarship" at Hangzhou Medical
					College."

Tigermed works with top hospitals and has developed a unique and innovative CRC training model, which will help the domestic healthcare industry build core competitiveness.

Tigermed jointly develops clinical research- related courses with universities and colleges, which will help arouse students' interest in clinical research, and thereby cultivate talents for the industry.

The China-South Korea clinical research exchange and cooperation platform creates good opportunities for building an international industry-university-research team.

Tigermed expands employment channels for college students and creates opportunities for students to know more about clinical research, so as to build a sustainable talent pool.

Tigermed supports clinical research education by improving school conditions. Tigermed strives to boost its attractiveness to talents and enhance the popularity of clinical research in universities.

The CRO industry is currently in a stage of rapid development, with a growing demand for high- quality talents. To achieve further progress and high-quality development, advance preparation and talent pooling matter. We invest a lot in finding industry talents and building a clinical research talent pool by adding systematic clinical research courses to the current medical education curriculum and adding clinical research-related content to the standardized training of resident doctors.

Students may not have a clear idea of what kind of job they want to take. The project of cooperation between schools and enterprises provides us with a valuable opportunity to understand the CRO industry. The project has equipped me with not only theoretical knowledge, but also hands-on skills, and prepared me for the industry and the job in a short time.

---Xu Siqing, an intern and then an employee of Tigermed Graduated from Zhejiang Pharmaceutical College in 2019

Tigermed carries out extensive cooperation to train talents for the future

Tigermed gives play to its resources and technical expertise to provide financial and technical support for start-up pharmaceutical companies, contributing to the lasting development of the innovative healthcare industry.

Funded Pharmaceutical Start-ups to Enable Their Rapid Growth

Case

At present, pharmaceutical innovation in China is in its infancy, and high-quality innovation projects are often forced into suspension due to lack of financial and technical support. Tigermed has directly invested in a number of leading biopharmaceutical companies in China, such as CANbridge, Genor Biopharma and Shanghai Zerun Biotechnology. Among them, Shanghai Zerun Biotechnology leads the domestic industry in the clinical progress of the 9-valent HPV vaccine. And Genor Biopharma plans to launch several new drugs within two years. Besides direct investment, we have also invested in eight leading domestic healthcare funds, in the hope of providing both financial and intellectual support to innovative healthcare industries like innovative drugs, innovative medical devices, medical AI, big data, and cellular immunotherapy. Our investment will empower recipient enterprises and drive the development of China's healthcare industry.

36

37

TIGERMED

Sustainability Report

ENSURING EMPLOYEES'

BASIC RIGHTS AND

INTERESTS

ACTIVATING TALENT

AND UNLEASHING

POTENTIAL

GUIDING OUR PEOPLE IN THE QUEST FOR SUCCESS

Our Actions:

Protect the fundamental rights and interests of employees

Pay attention to employee growth and development Care for female employees

Talents are invaluable assets and the cornerstone of sustainability for Tigermed. We always put people first, respect the value of employees, and support them in career development. While helping employees grow and fulfill themselves, we retain them and grow into a talent- backed industry leader.

FOSTERING AN ENGAGING TIGERMED CULTURE

TIGERMED

Sustainability Report

GUIDING OUR PEOPLE IN THE QUEST FOR SUCCESS

CEO's View on Talents

• People-centeredApproach for Common Development

Talents define Tigermed's core competitiveness. While we are growing fast, we adopt a more scientific and reasonable approach in selecting, employing, training and retaining talents. Our employees have a strong sense of happiness, not only because they echo with our corporate culture, but also because they find Tigermed to be the right place for unleashing their talent. While our employees strive for excellence in work, we give them all-round support and care in mental health counseling, relocation and returning to work after childbirth, etc. Such challenges are fully identified and properly handled at Tigermed. We are committed to becoming a talent magnet in the CRO industry and keep investing in a stable and high-quality talent pool.

ENSURING EMPLOYEES' BASIC RIGHTS AND INTERESTS

We act in strict accordance with relevant laws and regulations, such as the Labor Law of the People's Republic of China and the Company Law of the People's Republic of China, international conventions and labor standards, and eliminate child labor and forced labor. We effectively protect the legitimate rights and interests of employees, and endeavor to maintain equal and harmonious labor relations. All our employees are treated equally regardless of gender, age, educational background, ethnicity and nationality, and enjoy equal and inclusive development and promotion opportunities.

Key Indicators

100%

Employee labor contract signing rate

100%

Social insurance coverage

Consolidating the Compensation and Performance Management System

Tigermed offers diversified salary packages to win the war for talent in the pharmaceutical R&D industry. We combine salary with equity incentives, and evaluate the performance of employees by introducing multi-dimensional KPIs to perfectly balance employees' efforts and gains. We have formulated a set of human resource management systems such as the Employee Handbook, Organization Performance Management System, Employee Performance Management System and Remuneration Management System, to ensure the openness and transparency of the performance evaluation standards and procedures for directors, supervisors and senior executives, as well as the transparency and law compliance of the appointment of senior executives.

Occupational Health and Safety

EmployeesProfessional teams Excellent educational backgroundEmployees worldwide

	Technical staff		Master's degree		4959
4959	Financial		Asia-pacific region [China included]
89.31%	and above
staff		239
Number of employees		1.63%	25.29%
	Marketing			Asia-pacific region [China excluded]
1064		staff	Junior	Bachelo's
	2.88%	428
Number of employees of		Administrative	college and	degree	North America
	staff	lower	12
the parent company		6.18%	11.71%	63.00%
					Europe

Note: The statistics above were current as at the end of December 2019. Please refer to "KEY PERFORMANCE" on P52-53 for more HR statistics.

40

Tigermed defines occupational health as mental and physical health. To ensure that clinical laboratories are health-friendly and safe, we have formulated safety management systems such as the Laboratory Facilities, Environment and Sanitation Procedures, and Procedures for Responding Risks and Opportunities, to keep testing and environmental facilities under strict control. We also arrange annual health checkups for employees, and all our employees received health checkups last year.

The CRO industry is full of challenges, and employees face high pressure from work and interpersonal relationships. To help employees better address challenges, we have launched the Employee Assistance Program (EAP), the first of its kind in the CRO industry.

41

• 泰格心福音 "EAP 启动海报

TIGERMED

Sustainability Report

ACTIVATING TALENT AND UNLEASHING POTENTIAL

			GUIDING OUR PEOPLE IN THE QUEST FOR SUCCESS
During the reporting
		Sparing no efforts in empowering employees
period
3580			Tigermed provides targeted training programs to employees at different levels and
Training	positions. From new hire training to MBA and EMBA degree education for senior
Number of employees trained	executives, from vocational skill training to management capacity building, we are
			committed to providing employees with uninterrupted and full-course training
			resources, to empower them and render them into productive, efficient and creative

Tigermed continues to help employees boost their value. We have formulated the Training Management Policy, Personal Training and relative SOPs, and on the basis of which, established a full-coverage,multi-pronged training framework. At Tigermed, one can learn anywhere, anytime as long as he or she wants. We offer a platform for employees to grow fast, and thus nurture and retain the high-quality talent team.

37	talents who have excellent problem-solving skills and take pride in their jobs.

Average training hours per
employee	Project Manager Enabling Program

Launching the recruitment management system

During the reporting period

4.67

Investment in employee training （million RMB）

To help employees better adapt to the new role as Project Manager (hereinafter referred to as PM), grow faster and improve team productivity, Tigermed has customized a two-year Backbone PM Enabling Program. The program aims to help PMs consolidate basic know-how, improve the ability of managing clinical trial projects, strengthen hands-on skills, and thereby lay a solid foundation for career development.

To meet the needs of Tigermed's group-oriented and international development,
and to build an employer brand of Tigermed, we integrate the recruitment of all
subsidiaries into one platform, and launch a recruitment management system	Selection
for full-process human resource management, including job vacancy posting,
candidate screening, ability assessment, and talent pool construction. The platform
allows us to continuously improve recruitment efficiency, and find top talents who
fit in with our vacancies and agree with our corporate values, thus laying a good
foundation for medium and long-term development of Tigermed.

192

Number of employees promoted through the professional talent channel

120

Number of employees promoted through the managerial talent

Book-reading and sharing						rning
Sharing project management
skills					a
			p
					e
		r	o	u	l
		G
Project review and summaryi
	g
Project experience sharing	n
	s
	r
	a
Case sharing	h
	a
		e
		s
				C	g
						ni

	T
r
nia

ID

P

	C
	o
	a
	c
	h
	i
g	n

Employees formulate IDPs

The Direct Manager provides assistance and reviews IDP progress on a quarterly basis

HRBP serves as the supervisor

Coaching PMs in key learning points every month, helping them adapt to the new role and build capacity

Trainees take notes in the monthly coaching

HRBP serves as the supervisor

Expanding the career development ladder

We offer a dual career development ladder for technical and managerial talents to

give full play to each employee's ability in the most suitable position and to fully Employment

channel

Specialized knowledge

Best practices in clinical trial project management

General skill training

The PM training program is mainly in five forms: IDP (Individual Development Plan), coaching, training, case sharing, and group learning. It aims to unleash constant and conscious enthusiasm of trainees for learning and growth and enable them to learn by themselves, so as to sustain long-term individual development.

recognize the value created by employees in different positions. To meet the needs
of business development, we added a site management promotion channel during
the reporting period as a novel and exclusive pipeline for CRCs on the frontline of
clinical research.
Internal Job Transfer Encourages Proactive Career Management of Employees	Case

Tigermed is fully aware that employees may seek job transfer at different stages of life due to personal or family reasons, to obtain opportunities for further fulfilling themselves. To this end, we have put in place an internal job transfer mechanism. When an employee applies for a job transfer, as long as there is a vacancy and the applicant is qualified, he or she can switch the role unimpededly. During the reporting period, 55 employees had switched positions, including CRCs, CRAs and senior executives who have been with Tigermed for more than 15 years.

During the reporting period

535

Key technical (business) personnel participating in the equity incentives program

Private Board meetings for senior executives

Senior executives at Tigermed often need to cope with complex and everchanging issues. Only with higher overall quality and leadership can they address challenges smoothly. During the reporting period, we organized three private Board meetings for the senior management team and invited coaches to strengthen their leadership and corporate management skills. At the same time, senior executives were paired up to solve management problems together. Such methods have helped improve the cohesion and capabilities of our senior management team.

Retaining key talents with incentive policies

During the reporting period, Tigermed continued to foster the KPI-oriented corporate Retention culture mainly based on company-level and department-level bonuses. We also released incentive measures such as equity incentives for talents at key positions and core managerial personnel, and continuously enhanced the competitiveness of our overall compensation package to attract outstanding external talents to join us.

Our employee turnover rate is lower than the industry average.

42

43

44

Reading salon for new employees to be familiar with corporate culture

Employees can give feedback and suggestions on corporate development through the internal IT platform, employee salons, Tigermed innovation talks and various other channels.

Internal Communication Mechanism of Tigermed

We optimize the reporting and instruction mechanism, and share professional knowledge and best practices across the Company through monthly meetings, Monthly Talking Points and live streaming.

Employee engagement

We inform employees of the Company's strategy and business performance, commend outstanding employees, and send holiday greetings via the email of the President Office of Administration, annual meetings, celebration activities, and HRBP email.

Middle management

TIGERMED Sustainability Report

FOSTERING AN ENGAGING TIGERMED CULTURE

Tigermed cares about how employees feel, listens to their needs, and provides them with all- round care and support, making the Company a big loving family.

An Unblocked Internal Communication Mechanism that Allows Employees to Share Their Views

Tigermed endeavors to establish an efficient internal communication mechanism that meets the new demands brought by business expansion and fresh blood, and ensures the accuracy, timeliness and transparency of information transmission.

Senior leadership

GUIDING OUR PEOPLE IN THE QUEST FOR SUCCESS

Supporting Work-life Balance of Employees

Tigermed attaches great importance to the work-life balance of employees and encourages employees to work hard and live a healthy life. We vigorously enrich employees' cultural life by providing benefits such as badminton clubs, football clubs, photography clubs, and free gyms to ease their work pressure. Employees are encouraged to participate in public welfare activities. They donated clothes to Limin Vocational School in Yushu Tibetan Autonomous prefecture of northwest China's Qinghai Province via the second "Love transcending distance" activity, and donated KRW 2.89 million (about RMB 17,315) to an orphanage in South Korea to support children in need. By doing this, employees themselves have become more responsible and more grateful.

68.29%

Women in management

2.67%

A year-on-year increase of

Tigermed Northern China Badminton Competition 2019

Caring for Female Employees

Tigermed pays attention to the workplace and life challenges faced by female employees, and responds to national policies of guaranteeing benefits and career development opportunities for women. We make it easier for female employees to become mothers by providing wedding leave, maternity leave, breastfeeding leave, prenatal care check-up leave, pregnancy leave, and birth control leave, and allow paternity leave for male employees. According to work arrangements, we create work flexibility for female employees in pregnancy and provide them with child care subsidies of the highest local standard. Moreover, we have set up maternity rooms in the Company to support new moms return to work. As of December 31, 2019, more than 1,000 "Tigermed babies" had been born.

"Tigermed babies"

45

TIGERMED

Sustainability Report

CONTRIBUTING

TO A SHARED

FUTURE

Our Actions:

Popularize knowledge of clinical trials

Support the "Small Shield" project for blocking hepatitis B mother-to-child transmission

Regulate waste disposal strictly Advocate green office

Healthy ecosystem and social system are the foundation for the survival and development of mankind. As a member of the global village, Tigermed links its own development with the goal of sustainable development of the world. While supporting drug R&D to protect people's health, we actively respond to climate change and other environmental challenges faced by the world, and take on the responsibility to increase public awareness of clinical trials, so as to change the world for the better.

GREEN TIGERMED:

STRENGTHENING

ENVIRONMENTAL

MANAGEMENT

CARING TIGERMED:

IMPROVING HEALTH

AWARENESS AT

COMMUNITY LEVEL

TIGERMED

Sustainability Report

CONTRIBUTING TO A SHARED FUTURE

GREEN TIGERMED:

STRENGTHENING ENVIRONMENTAL MANAGEMENT

Tigermed strictly complies with laws and regulations, such as the Environmental Protection Law of the People's Republic of China. We pursue green development in everyday office tasks and clinical research, and have gradually developed our own EHS (Environment, Health and Safety) management system by drawing from best practices of advanced industry peers. We are also integrating green development requirements into business operations to reduce our environmental footprint and achieve green development.

Regulating Waste Disposal Strictly

The Company's non-hazardous waste mainly includes office wastepaper, cleaning supplies waste, food waste, and hazardous waste mainly consists of toxic liquid waste generated during clinical trials. Reducing waste discharge is one of our environmental goals. To fulfill the goal, we sort and manage non-hazardous office waste in a rigorous manner, and handle it to environmental protection authorities for proper treatment on a regular basis. Laboratory environment management procedures have been formulated. And a specific department was established to be in charge of registering and handling laboratory waste, helping strengthen laboratory waste treatment and prevent the waste from affecting water and soil.

			Poured into designated recycling bins for waste liquid and
Laboratory		Low-toxic and non-toxic waste liquid
	collected regularly by partner agencies
	Waste acid and alkali	Discharged after being neutralized with dilute alkali or acid
waste		Exhaust gas	Chemical experiments that produce exhaust gases are done
	in labs with fume hoods to treat and vent exhaust gases
	Everyday solid waste	Landfilled after collection
disposal
	Biological waste	Inactivated before disposal

In 2019

88.453

Non-hazardous waste such as domestic and office waste (ton)

0.055

Emissions per capita （ton）

We hand over hazardous office waste, such as empty toner cartridges and waste fluorescent tubes, to third-party agencies or the real estate management service for disposal.

In 2019

0.0640

Electricity consumption per capita (10000 kWh)

32.6087

Water consumption per capita （ton）

In 2019

181.561

The Company's total direct and indirect greenhouse gas emissions decreased by 181.561 tons CO2e on a year-on-year basis.

Saving Resources

We strictly control water and electricity use by continuously strengthening the inspection and maintenance of water equipment and facilities, phasing out outmoded electricity-consuming appliances, and managing water and electricity consumption statistics. We have enhanced employees' awareness of resource conservation through communication, putting up slogans on saving water and electricity and other means to help build a resource-saving society. We use municipal water and haven't posed any major risk to the environment.

		Purchased electricity by Tigermed's possessed		Water consumption (Unit: Ton)
2017		and leased properties (Unit: 10000 kWh)	2017
					128.9931						61298
2018														2018
					125.9178						58268
2019														2019
			103.3363							52663
		30	60	90	120	150				50000 53000 56000 59000 62000

Catchy electricity slogan in the office area

Combating Climate Change

As a CRO, Tigermed's day-to-day energy consumption mainly comes from electricity consumption of office equipment such as computers and lighting facilities, and oil consumption of vehicles. We keep a close eye on the impact of our daily operation on climate change, and work hard to reduce pollution by launching a remote online collaborative office system, promoting green office (such as replacing printed business cards with electronic ones), and effectively controlling and managing self-owned vehicles.

Note: Please refer to "KEY PERFORMANCE" on P52-53 for the scope and calculation method of environmental data, and more emissions statistics.

831.444

Indirect greenhouse gas (Scope 2) emissions （ton CO2e)

0.515

Emissions per capita （ton CO2e) Calculated based on the Company's purchased electricity

65.834

Direct greenhouse gas (Scope 1) emissions （ton CO2e）

0.041

Emissions per capita （ton CO2e） Calculated based on the Company's gasoline consumption

48

49

TIGERMED

Sustainability Report

CONTRIBUTING TO A SHARED FUTURE

CARING TIGERMED: IMPROVING HEALTH AWARENESS AT COMMUNITY LEVEL

We answer questions from subjects on the CRPF official WeChat account:

Q Subject

A Doctor

Doctor, are the trials and tests free? What obligations do I need to fulfill?

The development of an enterprise is inseparable from the engagement and support of the community, while the development of a community also requires the invention and contribution of enterprises. For Tigermed, health is a key issue on our agenda to contribute to community development. We strive to open a communication channel between the Company and society, spread our health philosophy to more people through benign interactions, and thereby enhance health awareness of the entire society.

Popularizing Knowledge about the Clinical Trials of Drugs

Clinical trials are still misunderstood by the general public. Most people believe they will be treated like "guinea pigs" in such trials and won't benefit much. However, clinical trial is a key link before bringing a new drug to the market, and the participation of subjects is indispensable. In fact, subjects could access new drugs or new therapies with better efficacy for free in clinical trials. Thus, Tigermed is actively popularizing knowledge of clinical trials among the public, helping the general public, especially subjects, know that such trials are scientific and advanced. By doing this, the Company contributes to building a healthy, virtuous, and trustworthy pharmaceutical R&D ecosystem.

In September 2017, Tigermed and large hospitals, pharmaceutical companies and other organizations from across China jointly established the Clinical Research Promotion Fund (CRPF), and opened an official WeChat account to popularize clinical research knowledge, publish latest news on clinical research, and educate subjects.

In November 2019

The "Small Shield" APP obtained the medical device license of Auxiliary Management Software for Blocking Mother- to-ChildTransmission of Hepatitis B issued by the Zhejiang Medical Products Administration. It was the first officially approved mobile APP software device license in the field of liver disease prevention and treatment since the implementation of the new list.

Hi, we encourage and respect every subject for the clinical trials of a new drug. Since the uncertainties and safety issues are unknown before a new drug is launched to the market, to avoid risks, it is necessary for subjects to take regular tests in accordance with the protocol. In this way, to comply with necessary obligations is to better protect the rights and interests of subjects themselves, and to ensure the safety of clinical trials.

The CRPF uses vivid animation to disseminate knowledge about clinical trials to the media and the public:

Scan the QR code to learn about	Scan the QR code to learn about
clinical trials of new drugs	clinical trials of generic drugs

My genuine opinion (on being a subject) is that patients spend less or even no money to get good treatment, while also providing true data for the R&D of the new drug and paving the way for future drug users. It is beneficial to the subjects themselves, to drug R&D institutions, and to future subjects.

---A comment on the CRPF official WeChat account

Blocking Mother-to-Child Transmission of Hepatitis B with the "Small Shield"

In 2015, the "Zero Mother-to-Child Transmission of Hepatitis B" project (the "Small Shield"), initiated by the Chinese Foundation for Hepatitis Prevention and Control and fully supported by Tigermed, was officially launched. With the establishment of the management network that includes pregnancy demonstration bases, project hospitals and community-level hospitals, and with the help of the "Small Shield" APP, a mobile medical tool developed by the Company's investee Hangzhou SlanHealth Co., Ltd., the project aims to carry out follow-up management of pregnant women with hepatitis B and their babies in accordance with standard procedures to minimize or even completely block mother-to-child transmission of the disease. As of the end of the reporting period, the "Small Shield" project had covered nearly 200 hospitals in 31 provinces, municipalities, and autonomous regions, with more than 1,600 registered doctors serving 30,000 expectant mothers carrying hepatitis B virus. The success rate of blocking mother-to-child transmission was above 99.5%.

50

51

TIGERMED

Sustainability Report

KEY

PERFORMANCE

	Economic performance
Indicator	Unit	2019	2018	2017
Total assets	RMB 100 million	75.33	42.80	35.83
Operating revenue	RMB 100 million	28.03	23.01	16.87
Net profit of shareholders of listed companies	RMB 100 million	8.42	4.72	3.01
Taxes payable	RMB 100 million	1.12	0.79	0.43
Basic earnings per share	RMB per share	1.13	0.94	0.61
Number of R&D personnel	/	468	426	378
Proportion of R&D personnel	%	9.44	10.93	11.76
R&D investment	RMB 100 million	1.24	0.88	0.50
R&D investment to operating revenue	%	4.43	3.83	2.94
Drug clinical research project	/	287	283	218

KEY PERFORMANCE

Social performance
Indicator	Unit	2019	2018	2017
Total count of active employees	/	4959	3898	3214
Female employees	/	4217	3233	2667
Employees aged 30 and below	/	3623	2874	2320
Employees aged 31 to 50	/	1296	994	860
Employees aged 51 and above	/	40	30	34
Women in management	%	68.29	65.62	66.84
Average paid vacation days	/	13.85	12.34	9.3
HSE investment	RMB 10000	740	620	460
Health checkup coverage	%	100	100	100
Staff turnover rate	%	18.7%	20.7%	23.0%
Work-related fatalities	/	0	0	0
Number of suppliers	/	1604	1896	1507
Cumulative donations	RMB 10000	870.60	767.60	652.60
Environmental performance
Indicator	Unit	2019	2018	2017
Non-hazardous waste such as domestic waste and office waste	Ton	88.453	73.950	59.520
Purchased electricity by Tigermed's possessed and leased	10000 kWh	103.3363	125.9178	128.9931
properties
Water consumption	Ton	52663	58268	61298
Mileage of the Company's light vehicles (<=2.5 tons)	Kilometer	112567	105548	95477
Mileage of the Company's light vehicles (2.5-3.5 tons)	Kilometer	132000	130000	135000
Gasoline consumption	Liter	24312	24264	23332
Emission of nitrogen oxides	Kilogram	252.03	243.51	240.37
Emission of particulates	Kilogram	23.74	22.93	22.61
Emission of sulfur oxides	Kilogram	0.36	0.37	0.34
Direct greenhouse gas (Scope 1) emissions	Ton	65.834	65.704	63.180
Indirect greenhouse gas (Scope 2) emissions	Ton	831.444	1013.135	1037.878

Note 1: The environmental data comes from Tigermed's Hangzhou Office, Jiaxing Office and Shanghai Office. The Company will gradually expand statistics management to cover the entire group.

Note 2: The emission of nitrogen oxides and particulate matter are calculated based on the mileage of light vehicles held by the company; the emission of sulfur oxides and direct greenhouse gases (Scope 1) are calculated based on gasoline consumption; and the emission of indirect greenhouse gases (Scope 2) are calculated based on purchased electricity. The calculation method is in line with the environmental KPI reporting principles in the Environmental, Social and Governance Reporting Guide (ESG Guide) formulated by Hong Kong Stock Exchange. The emission coefficient of indirect greenhouse gases (Scope 2) is 0.8046, which is derived from the China Regional Power Grid Baseline Emission Factors for Emission Reduction Projects in 2017 issued by the Ministry of Ecology and Environment.

52

53

TIGERMED

Sustainability Report

In an ever changing world, change is the only constant. Successful organizations bear the mark of the times.

--by John P. Kotter, author of Leading Change

OUTLOOK

In the global wave of pharmaceutical innovation, the emergence of new technologies like big data and AI and breakthrough therapies will change the original CRO model. As China has become the second largest pharmaceutical market in the world, and Healthy China 2030 has become a national strategy, the government is now vigorously promoting pharmaceutical innovation by mounting policy, capital, and industry support. Tigermed will actively embrace the era of pharmaceutical R&D and innovation, stand firm on being quality- oriented and innovate in services to cope with changes in the industry and across the world.

In 2020, Tigermed will stay true to the mission of "service innovation, health for all" and adhere to the strategy of "Excellence in Every Trial for Every Patient" to serve the cause of innovative medicine. We will orient our efforts toward customer demand and globalization, expedite the set-upof a global clinical service network, and continuously improve the ability of operating and managing global projects, thus providing integrated solutions and one-stopservices for global pharmaceutical R&D, and contribute to the health of humankind.

Quality and qualification

Riding on the global trend of pharmaceutical R&D, we will consolidate SOPs of subsidiaries, continuously optimize quality management procedures, and foster a quality culture with full participation of employees, in an effort to build Tigermed into a CRO aligned with global quality management standards.

Market strategy

We pay attention to new business drivers such as real-world evidence (RWE), with a focus on developing non-regulated businesses. We will go global together with our customers, and build an international operation team with the support of overseas projects of our strategic customers, so as to expand our market to the Asia-Pacific, North America and Western Europe.

Innovation-driven development

We closely follow frontier technologies in the industry and develop our own leading technologies based on strengths in different business lines. We will follow up with innovative business models such as RWE and risk- based monitoring (RBM), and improve customer service procedures through innovation.

OUTLOOK

Talent strategy

In terms of human resource management, we will stick to the people-centered approach for common development, and create a sound development platform for employees. We retain employees with corporate culture and career growth opportunities, and grow along with them.

Excellent operation

We have established a global operation system. With a competent and stable team and reliable quality assurance, we will be able to deliver 100% projects on time with guaranteed quality, and sustain our competitive profitability.

Customer first

We are always customer-focused. We will timely learn and analyze the needs and expectations of customers and the market, and continue to optimize customer relationship management, improve the communication mechanism and complaint management, and strive to become a trustworthy clinical research partner.

Responsibility management

We will further implement the sustainable development philosophy by formulating and improving policies and regulations and strengthening the roles of key departments, especially the Board of Directors, in the sustainability management of Tigermed.

54

55

TIGERMED

Sustainability Report

HONG KONG STOCK EXCHANGE ESG (ENVIRONMENTAL, SOCIAL AND GOVERNANCE) REPORTING GUIDE INDEX

This report has complied with the "non-compliance and interpretation" provisions set out in the Environment, Social and Governance Reporting Guidelines.

Aspect		Environmental
	Indicator	Page	Note
		Information on:
	General	(a) the policies; and	P48-49
	(b) compliance and material non-compliance with relevant standards, rules and
	Disclosure	regulations on air and greenhouse gas emissions, discharges into water and land,
		and generation of hazardous and non-hazardous waste
	A1.1	The types of emissions and respective emissions data	P53
	A1.2	Greenhouse gas emissions in total (in tons) and, where appropriate, intensity (e.g.	P49
A1 Emissions	per unit of production volume, per facility)
	Total hazardous waste produced (in tons) and, where appropriate, intensity (e.g. per		We entrust a third party to
	A1.3	P48	dispose of hazardous office
	unit of production volume, per facility)	waste and do not acquire
				relevant data
	A1.4	Total non-hazardous waste produced (in tons) and, where appropriate, intensity (e.g.	P48
	per unit of production volume, per facility)
	A1.5	Description of measures to mitigate emissions and results achieved	P48
	A1.6	Description of how hazardous and non-hazardous wastes are handled, reduction	P48
	initiatives and results achieved
	General	Policies on the efficient use of resources, including energy, water and other raw
	materials.	P49
	Disclosure	Resources may be used in production, in storage, transportation, in buildings,
		electronic equipment, etc.
	A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total	P49
A2 Use of	(kWh in '000s) and intensity (e.g. per unit of production volume, per facility)
A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per	P49
Resources	facility)
	A2.3	Description of energy use efficiency initiatives and results achieved	P49
	A2.4	Description of whether there is any issue in sourcing water that is fit for purpose,	P49
	water efficiency initiatives and results achieved
	A2.5	Total packaging material used for finished products (in tons) and, if applicable, with	Not	Our clinical research of
	drugs do not involve
		reference to per unit produced	applicable	packages
A3 The	General	Policies on minimizing the operation's significant impact on the environment and	P48-49
Environment	Disclosure	natural resources
and Natural	A3.1	Description of the significant impacts of activities on the environment and natural	P49
Resources	resources and the actions taken to manage them.
Aspect 4:	General	Policies on identification and mitigation of significant climate-related issues which	/
Disclosure	have impacted, and those which may impact, the issuer.
Climate Change
A4.1	Description of the significant climate-related issues which have impacted, and those	P49
	which may impact, the issuer, and the actions taken to manage them.
Aspect		Social
	Indicator	Page	Note
		Information on:
	General	(a) the policies; and
	(b) compliance and material non-compliance with relevant standards, rules and	P40-41
B1 Employment	Disclosure	regulations on compensation and dismissal, recruitment and promotion, working
	hours, rest periods, equal opportunity, diversity, anti-discrimination, and other
		benefits and welfare
	B1.1	Total workforce by employment type, age group and geographical region	P40
	B1.2	Employee turnover rate by age group and geographical region	P53

HONG KONG STOCK EXCHANGE ESG (ENVIRONMENTAL,

SOCIAL AND GOVERNANCE) REPORTING GUIDE INDEX

				We comply with China's
		Information on:		laws and regulations,
	General		including Work Safety Law
	(a) the policies; and	P41	of the People's Republic of
B2 Health and	Disclosure	(b) compliance and material non-compliance with relevant standards, rules and	China, and Prevention and
	regulations on providing a safe working environment and protecting employees		Control of Occupational
Safety		from occupational hazards		Diseases Law of the
				People's Republic of China
	B2.1	Number and rate of work-related fatalities	P53
	B2.2	Lost days due to work injury.	/
	B2.3	Description of occupational health and safety measures adopted, how they are	P41
	implemented and monitored
	General	Policies on improving employees' knowledge and skills for discharging duties at	P42-43
B3 Development	Disclosure	work. Description of training activities
B3.1	The percentage of employees trained by employee category (e.g. senior	P43
and Training	management, middle management)
	B3.2	The average training hours completed per employee by employee category	P43
	General	Information on:
	(a) the policies; and	P40
B4 Labor	Disclosure	(b) compliance and material non-compliance with relevant standards, rules and
	regulations on preventing child and forced labor
Standards
B4.1	Description of measures to review employment practices to avoid child and forced	P40
	labor
	B4.2	Description of steps taken to eliminate such practices when discovered	/	No violation
	General	Policies on managing environmental and social risks of the supply chain.	P11, P29
	Disclosure
B5 Supply Chain	B5.1	Number of suppliers by geographical region	P29
B5.2	Description of practices relating to engaging suppliers, number of suppliers where	P29
Management		the practices are being implemented, how they are implemented and monitored.
B5.3	Description of practices used to identify environmental and social risks along the	P29
	supply chain, and how they are implemented and monitored.
	B5.4	Description of practices used to promote environmentally preferable products and	P29
	services when selecting suppliers, and how they are implemented and monitored.
		Information on:		We comply with China's
			laws and regulations,
	General	(a) the policies; and	P26-29	including Drug
	(b) compliance and material non-compliance with relevant standards, rules and	Administration Law of the
	Disclosurea	regulations on health and safety, advertising, labelling and privacy matters relating		People's Republic of China,
		to products and services provided and methods of redress		and Provisions for Drug
				Registration.
B6 Product	B6.1	Percentage of total products sold or shipped subject to recalls for safety and health	/	No such incident
reasons.
Responsibility
B6.2	Number of products and service related complaints received and how they are dealt	P27
	with
	B6.3	Description of practices relating to observing and protecting intellectual property	P12
	rights
	B6.4	Description of quality assurance process and recall procedures.	P27-28
	B6.5	Description of consumer data protection and privacy policies, how they are	P26
	implemented and monitored
	General	Information on:
	(a) the policies; and	P10-11
	Disclosure	(b) compliance and material non-compliance with relevant standards, rules and
B7 Anti-		regulations on bribery, extortion, fraud and money laundering
B7.1	Number of concluded legal cases regarding corrupt practices brought against the	/	No such litigation
corruption	issuer or its employees during the reporting period and the outcomes of the cases.
	B7.2	Description of preventive measures and whistle-blowing procedures, how they are	P11
	implemented and monitored
	B7.3	Description of anti-corruption training provided to directors and staff.	P10-11
	General	Policies on community engagement to understand the communities' needs where	P50-51
	it operates and to ensure its activities take into consideration the communities'
B8 Community	Disclosure	interests
Investment	B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs,	P50-51
	health, culture, sport)
	B8.2	Resources contributed (e.g. money or time) to the focus area	P53

56

57

TIGERMED

Sustainability Report

GRI (GLOBAL REPORTING INITIATIVE)

INDEX

This report has been prepared in accordance with the GRI Standards: Core option.

	Disclosure Items	Page	Note
	102-1 Name of the organization	P04
	102-2 Activities, brands, products, and services	P04-06
	102-3 Location of headquarters	P06
	102-4 Location of operations	P06
	102-5 Ownership and legal form	P04
Organizational profile	102-6 Markets served	P06
102-7 Scale of the organization	P06,P40
	102-8 Information on employees and other workers	P40
	102-9 Supply chain	P29
	102-10 Significant changes to the organization and its supply chain	P08
	102-11 Precautionary Principle or approach	P12
	102-13 Membership of associations	P24
Strategy	102-14 Statement from senior decision-maker	P02-03
102-15 Key impacts, risks, and opportunities	P02-03,P12
Ethics and integrity	102-16 Values, principles, standards, and norms of behavior	P06
102-17 Mechanisms for advice and concerns about ethics	P12
	102-18 Governance structure	P08
Governance	102-29 Identifying and managing economic, environmental, and social impacts	P14
102-30 Effectiveness of risk management processes	P12
	102-31 Review of economic, environmental, and social topics	P14
	102-32 Highest governance body's role in sustainability reporting	P13
	102-40 List of stakeholder groups	P15
	102-42 Identifying and selecting stakeholders	P15
	102-43 Approach to stakeholder engagement	P15
	102-44 Key topics and concerns raised	P15
	102-46 Defining report content and topic Boundaries	P15,P60
	102-47 List of material topics	P15
	102-48 Restatements of information		No restatements of
Stakeholder engagement		information
102-49 Changes in reporting		No significant
		changes
	102-50 Reporting period	P60
	102-51 Date of most recent report	P60
	102-52 Reporting cycle	P60
	102-53 Contact point for questions regarding the report	P60
	102-54 Claims of reporting in accordance with the GRI Standards	P58
	102-55 GRI content index	P58

GRI (GLOBAL REPORTING INITIATIVE) INDEX

	Disclosure Items	Page	Note
GRI 200 Economic	GRI 103 Management Approach	P8-12,P22-29
GRI 201 Economic	201-1 Direct economic value generated and distributed	P52
Performance	201-3 Defined benefit plan obligations and other retirement plans	P41,P43
GRI 203 Indirect Economic	203-2 Significant indirect economic impacts	P51
	GRI 103 Management Approach	P10-11
GRI 205 Anti-corruption	205-2 Communication and training about anti-corruption policies and	P10-11
procedures
	205-3 Confirmed incidents of corruption and actions taken		No corruption
GRI 206 Anti-competitive	206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly		No such litigation
Behavior	practices
GRI 300 Environment	GRI 103 Management Approach	P48-49
GRI 302 Energy	302-1 Energy consumption within the organization	P49
GRI 303 Water	303-1 Water withdrawal by source	P49
303-2 Water sources significantly affected by withdrawal of water	P49	No such influence
	305-1 Direct (Scope 1) GHG emissions	P49
GRI 305 Emissions	305-2 Energy indirect (Scope 2) GHG emissions	P49
305-5 Reduction of GHG emissions	P49
	305-7 Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air	P53
	emissions
GRI 306 Effluents and Waste	306-2 Waste by type and disposal method	P48
306-3 Significant spills		No significant spills
GRI 307 Environmental	307-1Non-compliance with environmental laws and regulations		No violation
Compliance
GRI 400 Society	GRI 103 Management Approach	P38-44,P50-51
GRI 401 Employment	401-1 New employee hires and employee turnover	P53
401-2 Benefits provided to full-time employees that are not provided to	P40-43
	temporary or part-time employees
GRI 404 Training and	404-1 Average hours of training per year per employee	P43
404-2 Programs for upgrading employee skills and transition assistance
Education	P42-43
programs
GRI 405 Diversity and Equal	GRI 103 Management Approach	P40
405-1 Diversity of governance bodies and employees	P40
Opportunity
	405-2 Ratio of basic salary and remuneration of women to men	P41
GRI 406 Non-discrimination	406-1 Incidents of discrimination and corrective actions taken		No discrimination
GRI 408 Child Labor	408-1 Operations and suppliers at significant risk for incidents of child labor		No such incident
GRI 409 Forced or	409-1 Operations and suppliers at significant risk for incidents of forced or		No such incident
Compulsory Labor	compulsory labor
GRI 411 Rights of Indigenous	411-1 Incidents of violations involving rights of indigenous peoples	P10	No such incident
Peoples
GRI 413 Local Communities	GRI 103 Management Approach	P45,P5-51
413-2 Operations with significant actual and potential negative impacts on local		No such location of
	communities		operations
GRI 414 Supplier Social	414-1 New suppliers that were screened using social criteria	P11
Assessment
GRI 417 Marketing and	417-1 Requirements for product and service information and labeling	P26
417-2 Incidents of non-compliance concerning product and service information		No such incident
Labeling	and labeling
	417-3 Incidents of non-compliance concerning marketing communications		No such incident
GRI 419 Socioeconomic	GRI 103 Management Approach	P10-12
419-1Non-compliance with laws and regulations in the social and economic
Compliance		No violation
area

58

59

TIGERMED

Sustainability Report

ABOUT

THIS REPORT

Reporting Period

The time frame for the report is January 1 to December 31, 2019, though some contents may extend beyond the stated reporting period.

Release Cycle

The report is released annually. And the first social responsibility report was released on August 22, 2019.

Reporting Boundary

This report covers Tigermed's headquarters and subsidiaries. For the convenience of readers, "Hangzhou Tigermed Consulting Co., Ltd." is also referred to as "Tigermed", "the Company" and "we" in the report. "Hangzhou Simo Co., Ltd." is referred to as "Hangzhou Simo". "MacroStat (China) Clinical Research Co., Ltd." is referred to as "MacroStat". "Jiaxing Tigermed Data Management Co., Ltd." is referred to as "Jiaxing Tigermed". "Jiaxing Clinflash Computer Technology Co., Ltd." is referred to as "Jiaxing Clinflash". "Hangzhou Talent MedConsulting Co., Ltd." is referred to as "Talent MedConsulting". "Frontage Laboratories, Inc." is referred to as "Frontage Laboratories". "Fantastic Bioimaging Co., Ltd." is referred to as "Fantastic Bioimaging", and "Teddy Clinical Research Laboratory (Shanghai) Limited" is referred to as "Shanghai Teddy".

Reporting Commitment

Tigermed assures that the report contains no false records, misleading information or material omission, and is responsible for the authenticity, accuracy, and integrity of its content.

Data Sources

Data in the report is mainly from the statistical reports and official documents of Tigermed from January 1 to December 31, 2019.

Compilation Conformance

This report is compiled in accordance with the ISO 26000: Guidance on Social Responsibility, the GRI Sustainability Reporting Standards (GRI Standards) issued by Global Sustainability Standard Board (GSSB) and the Environmental, Social and Governance Reporting Guide (ESG Guide) formulated by Hong Kong Stock Exchange.

Contact Us

Corporate Social Responsibility Department, Tigermed

Email：[e-mail]

For more information about Tigermed's CSR practices, please go to https://tigermedgrp.com/

Note: Tigermed's headquarters (Hangzhou) relocation is estimated to be completed by the end of	Scan the QR code to give
August 2020. Please refer to our official website for the new address.	feedback on the report.

60